Karyopharm Therapeutics SG&A Expense (Quarterly) Insights

Karyopharm Therapeutics Inc (KPTI)

1.15 +0.02 (+1.32%) USD | NASDAQ | May 17, 16:00

1.15 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2012. Upgrade now.

Date	Value
March 31, 2024	29.55M
December 31, 2023	30.69M
September 30, 2023	30.80M
June 30, 2023	34.48M
March 31, 2023	35.91M
December 31, 2022	34.65M
September 30, 2022	34.64M
June 30, 2022	37.34M
March 31, 2022	38.77M
December 31, 2021	34.56M
September 30, 2021	35.10M
June 30, 2021	36.53M
March 31, 2021	37.65M
December 31, 2020	33.93M
September 30, 2020	30.97M
June 30, 2020	30.84M
March 31, 2020	30.68M
December 31, 2019	28.39M
September 30, 2019	25.27M
June 30, 2019	24.66M
March 31, 2019	27.10M
December 31, 2018	18.77M
September 30, 2018	12.97M
June 30, 2018	9.489M

Date	Value
March 31, 2018	7.621M
December 31, 2017	6.153M
September 30, 2017	5.818M
June 30, 2017	6.635M
March 31, 2017	6.264M
December 31, 2016	6.541M
September 30, 2016	5.897M
June 30, 2016	5.956M
March 31, 2016	5.554M
December 31, 2015	5.264M
September 30, 2015	4.762M
June 30, 2015	6.157M
March 31, 2015	5.399M
December 31, 2014	5.92M
September 30, 2014	3.814M
June 30, 2014	3.31M
March 31, 2014	2.904M
December 31, 2013	2.48M
September 30, 2013	1.583M
June 30, 2013	0.943M
March 31, 2013	0.879M
December 31, 2012	0.605M
September 30, 2012	0.672M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

24.66M

Minimum

Jun 2019

38.77M

Maximum

Mar 2022

32.77M

Average

34.20M

Median

SG&A Expense (Quarterly) Benchmarks